Patients with PH-HFpEF develop more severe symptoms than those with HFpEF and suffer significant exercise intolerance, frequent hospitalizations, RV failure, and reduced survival Pulmonary hypertension (PH) due to left heart disease (LHD) is the most frequent form of PH and is a growing public health problem with associated high morbidity and mortality (Vachiery et al. 2013) . PH-LHD was originally classified under category 2 (pulmonary venous hypertension) with predominant cause of left-sided valvular or myocardial diseases by the World Health Organization (WHO) in 1998. During the Fifth World Symposium on Pulmonary Hypertension held in Nice, France in 2013, the classification was updated and the subcategories of Group 2 PH/PH-LHD were classified into four distinct aetiologies: left ventricular (LV) systolic dysfunction, LV diastolic dysfunction, valvular disease, and congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies . Most recently, the 2015 European Society of Cardiology (ESC) and the European Respiratory society (ERS) guidelines further expanded the definitions to include congenital/acquired pulmonary vein stenosis in Group 2 PH (Galie et al. 2016a) . Among all of these LHD endophenotypes, PH attributable to LV diastolic dysfunction, also referred to as PH associated with heart failure with preserved ejection fraction (PH-HFpEF), is clearly the most common (Willens & Kessler, 1993; Lam et al. 2009) . Although the true prevalence of PH-HFpEF remains unknown due to a general lack of standardization in study design (mostly retrospective and single centre), with accompanying variation in the definitions and diagnostic methods used (most data are based on echocardiography estimation rather than invasive haemodynamic measurement with right heart catheterization), the range in the reported prevalence of PH is between 23% and 83% of patients with HFpEF (see recent reviews for detailed information: Vachiery et al. 2013; Guha et al. 2016; Levine et al. 2018) . Qualitative studies have documented that patients with PH-HFpEF develop more severe symptoms than those with HFpEF and suffer significant exercise intolerance, frequent hospitalizations, right ventricular (RV) failure and reduced survival (Guazzi, 2014; Mohammed et al. 2014; Dalos et al. 2016; Gorter et al. 2016 Gorter et al. , 2018b Santas et al. 2017; Vanderpool et al. 2018) . Despite increasing interest and a growing number of related publications, no approved specific medication or consensus therapeutic strategy for PH-HFpEF is available at present, mainly due to significant gaps in understanding of the pathophysiological processes and parameters that can help to accurately define PH-HFpEF, as well as the complex associated comorbidities seen with HFpEF in general (metabolic syndrome, renal dysfunction, advancing age, etc.). In this review, we aim to provide an updated overview of the pulmonary vascular complications in HFpEF in terms of clinical definitions, epidemiology and pathophysiology. Mechanisms leading to pulmonary vascular remodelling in HFpEF, as well as pre-clinical models which aid evaluation of the putative therapeutic strategies for the treatment of PH-HFpEF, will also be discussed.
suffer from HFpEF (Benjamin et al. 2017) . Roughly half of these patients (a wide range from 23 to 83%, depending on the definitions employed) have associated high pulmonary artery pressures (i.e. PH), imposing an economic burden of about $7.7 billion per annum (Farr et al. 2016; Savarese & Lund, 2017) .
Evaluation of a patient with suspected PH in HFpEF requires comprehensive clinical, echocardiographic and haemodynamic assessments. Exertional dyspnoea and exercise intolerance are the most common symptoms in HFpEF patients and, together with orthopnoea and paroxysmal nocturnal dyspnoea, are often the first clues to the presence of PH. Individuals with PH-HFpEF are often elderly, female and more likely to present with multiple comorbidities, including obesity, diabetes mellitus, hypertension, renal dysfunction, coronary artery disease and atrial fibrillation. Findings from physical examination may reveal signs of fluid retention (e.g. peripheral oedema, ascites and crackles) and cardiac examination will reveal the presence of an S3 heart sound. Additionally, chest X-ray may show pulmonary vascular congestion, pleural effusion and pulmonary oedema. Screening echocardiography often reveals evidence of left atrial enlargement, LV hypertrophy, right atrial enlargement, LV diastolic dysfunction (e.g. abnormal LV relaxation, filling, dispensability or diastolic stiffness), and preserved LV systolic function (e.g. LV ejection fraction ࣙ50% and indexed LV end-diastolic volume <97 mL/m 2 ) (Rich & Rabinovitch, 2008; Guazzi & Borlaug, 2012; Perez et al. 2012) . Although mean pulmonary artery pressure (mPAP) can be estimated by echocardiography based on tricuspid regurgitant jet velocity, the accuracy of this is low. Thus, despite echocardiography being a good screening tool, it should never be used to establish a diagnosis of PH-HFpEF without proceeding with a right heart catheterization (Lai et al. 2014) . Diagnosis of PH-HFpEF is typically confirmed when the mPAP exceeds 25 mmHg and when pulmonary arterial wedge pressure (PAWP; also called pulmonary capillary wedge pressure (PCWP) or pulmonary artery occlusion pressure (PAOP)) is greater than 15 mmHg at rest (Fig. 1) . It is important to note that PAWP should be measured at end-expiration to minimize respiratory pressure swings. If there is further concern for coronary disease or discrepancy from previous right heart catheterization, left ventricular end-diastolic pressure (LVEDP) can be measured directly by left heart catheterization (Lai et al. 2014) . Elevated plasma levels of brain natriuretic peptide (BNP) (BNP ࣙ35 pg/mL and/or N-terminal prohormone of BNP (NT-proBNP) ࣙ125 pg/mL) are also frequently detected in patients with PH-HFpEF. Increased LA volume and higher pulmonary artery-to-aorta ratio measured by 
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Pre-capillary component cardiac magnetic resonance, as well as higher size ratio of left atrium to right atrium measured by non-gated CT angiography (CTA), may be additional diagnostic features for identifying patients with PH-HFpEF, although none of these have been sufficiently validated (Crawley et al. 2013; Karakus et al. 2015; Huis In 't Veld et al. 2016) .
As atrial fibrillation was observed in more than 65% of HFpEF patients and was correlated with right ventricular dysfunction in patients with HFpEF, (Zakeri et al. 2013; Melenovsky et al. 2014; Lam et al. 2017; Sartipy et al. 2017) , it is not surprising that the presence of atrial fibrillation was reported in 28-48% of patients with PH-HFpEF (Salamon et al. 2014; Berthelot et al. 2017) . Nonetheless, future studies are needed to determine whether the presence of atrial fibrillation can be employed as a diagnostic factor for PH-HFpEF. While most PH diagnoses rely on resting haemodynamics, HFpEF patients experience worsening symptoms indicative of PH more often during exercise due to a number of impairments in cardiovascular reserve function and skeletal muscle vasodilatory reserve with exercise. The use of exercise stress testing has been increasingly recognized as a valuable tool for the reproduction of symptoms and early diagnosis of PH-HFpEF, especially in patients with unexplained exertional symptoms and normal resting haemodynamics or in patients with intermediate probability of PH-HFpEF (Borlaug et al. 2010; Borlaug et al. 2011; Obokata et al. 2018) . The type of exercise stress testing can vary widely and may include the six-minute walk test (6MWT), cardiopulmonary exercise testing (CPET) and CPET combined with echocardiography and/or both right and left heart catheterization. Standard/non-invasive CPET records parameters such as oxygen uptake (V O 2 ), carbon dioxide production (V CO 2 ) and minute ventilation (V E ) during exercise, which can aid in diagnosis and risk stratification of PH-HFpEF as very low uprightV O 2 at peak exercise (<14 mL/kg/min) and increasedV E /V CO 2 slope (</ࣙ36), have been reported in patients with PH-HFpEF (Borlaug et al. 2010; Guazzi et al. 2013b; Reddy et al. 2018) . Using invasive CPET, a mPAP cut-off value of >30 mmHg at a cardiac output (CO) <10 L/min or a total pulmonary resistance (defined as mPAP/CO) >3 Wood units and a PAWP cut-off value of ࣙ25 mmHg during exercise have been proposed for the diagnosis of PH in patients with HFpEF ( Fig. 1) (Borlaug et al. 2010; Lewis et al. 2013; Maor et al. 2015) . In a recent study by Obokata et al., which employed a simultaneous use of non-invasive and invasive CPET, it was shown that increased left heart filling pressure and pulmonary artery pressure during exercise directly correlated with reduced exercise capacity, increased ventilatory drive, severity of dyspnoea, altered breathing patterns, lower RV systolic function, and worse functional class . These data reveal a new insight into the connection between haemodynamic derangements, clinical symptoms and gas exchange alterations in patients with PH-HFpEF. Additionally, limited data suggest that a PAWP cut-off value of 18 mmHg after fluid challenge with 7 mL/kg saline may be useful for the diagnosis of patients with post-capillary PH. Although the use of exercise exposure was suggested for detection of diastolic dysfunction in the current guidelines for the diagnosis and treatment of heart failure, the current guidelines for the diagnosis and treatment of pulmonary hypertension recommend against the use of these stress-inducing measures due to insufficient validation and lack of standardized protocols (Borlaug et al. 2010; Robbins et al. 2014; Ponikowski et al. 2016; Galie et al. 2016b; D'Alto et al. 2017; Obokata et al. 2018) .
Still, these definitions do not account for the presence or absence of progressive pulmonary vascular remodelling (also known as the pre-capillary component) associated with the development of PH in patients with HFpEF. Depending on the extent of the pre-capillary component, the backward transmission of the elevated LV filling pressure can lead to an increase in pulmonary artery pressure passively (1:1 ratio) or disproportionately (>1:1 ratio). Patients with no significant pulmonary vasoconstriction or pre-capillary component often exhibit passive/proportional PH (now termed isolated post-capillary PH, IpcPH) and are responsive to medications which lower their PAWP, such as diuretics, nitroprusside and other systemic blood pressure control drug. If, on the other hand, chronically elevated LV filling pressure triggers pulmonary vasoconstriction and pathological pre-capillary remodelling to a point of having increased pulmonary vascular resistance (PVR, defined as transpulmonary gradient (TPG)/CO) and high TPG (where TPG is defined as mPAP − PAWP), patients exhibit out of proportion PH (now termed combined pre-capillary and post-capillary PH, CpcPH). While increased PVR (>3 Wood units) and high TPG (>12 mmHg) are commonly used to differentiate patients with CpcPH from IpcPH (PVR <3 Wood units and TPG ࣘ12 mmHg), these parameters may not accurately reflect the presence of the pre-capillary component for their interdependence on CO and PAWP Task Force for et al. 2009 ). As diastolic pressure gradient (DPG, defined as diastolic PAP − PAWP) is independent of pulmonary blood flow and is not influenced by PAWP, a new haemodynamic definition for distinguishing CpcPH from IpcPH was proposed based on elevated DPG (ࣙ7 mmHg) during the Fifth World Symposium on PH (Stevens, 1975; Buchbinder & Ganz, 1976; Chemla et al. 2002; Gerges et al. 2013; Vachiery et al. 2013) . Beyond diagnosis, recent reports also showed the prognostic value of DPG, as elevated DPG was associated with increased mortality and poor long-term outcomes (Gerges et al. 2013; Ibe et al. 2016) . In accord with this, a large retrospective cohort study (Pittsburgh cohort, single centre with 10,023 subjects undergoing right heart catheterization during [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] revealed that multiple haemodynamic definitions of the pre-capillary component (elevated DPG, PVR and TPG) all independently predicted mortality and cardiac hospitalizations in patients with CpcPH-HFpEF (Vanderpool et al. 2018 ). This study found that TPG >12 mmHg (an easily obtained measure) captures more patients as having CpcPH and independently predicts hospitalization and increased mortality in patients with HFpEF. Furthermore, this study suggested that DPG measurement can lead to underestimation of CpcPH based on artefactual negative DPG values.
There is an increasing controversy regarding the use of DPG, as several retrospective studies have shown that DPG does not have predictive ability for survival and outcomes (Tedford et al. 2014; Brittain et al. 2015; Tampakakis et al. 2015; Adir et al. 2017 ). As mentioned above, another apparent major problem with using DPG comes from the reliability of its measurement, since even small errors in obtaining diastolic PAP (e.g. negative values caused by catheter 'whip' , high frequency noise, excessive respiratory variation, and/or inadequate calibration) and PAWP (e.g. inaccurate wedging or large V-waves) may significantly impact DPG, given its relatively low absolute value (Tampakakis et al. 2015; Nagy et al. 2017) . While further research is needed to determine whether or not haemodynamic definition by DPG is clinically meaningful, the current guidelines included both PVR and DPG, and redefined IpcPH as DPG <7 mmHg and/or PVR ࣘ3 Wood units and CpcPH as DPG ࣙ7 mmHg and/or PVR >3 Wood units ( Fig. 1) (Galie et al. 2016b) .
Chronic elevation in LV filling pressure and the progressive pulmonary vascular remodelling leads to reduced pulmonary artery compliance (PAC, defined as stroke volume/pulmonary artery pulse pressure), resulting in RV contractile impairment, increased pulsatile RV afterload, and eventually right heart failure. Within this context, PAC has been proposed as a new haemodynamic marker for diagnosis and prognosis of CpcPH-HFpEF (Al-Naamani et al. 2015; Dragu et al. 2015; Sugimoto et al. 2016) . Of note, PAC was found as the strongest predictor of mortality, compared to DPG, PVR and TPG, with low PAC (<1.1 mL/mmHg) associated with nearly a fivefold increased risk of death in patients with PH-HFpEF in a recent study (Al-Naamani et al. 2015) . Additionally, index of RV contractile function and its coupling with pulmonary circulation (RV-PC coupling), such as measurements of the ratio between end-systolic elastance (E es ) and arterial elastance (E a ), as well as the ratio between tricuspid annular plane systolic excursion (TAPSE) and pulmonary artery systolic pressure (PASP), were found useful for stratifying clinical phenotypes and predicting outcomes of patients with CpcPH-HFpEF. For instance, Gauzzi et al. showed that depressed TAPSE/PASP ratio predicts CpcPH-HFpEF and a TAPSE/PASP cut-off ratio of <0.36 is associated with worse prognosis. Gerges et al. also reported that poor RV-PC coupling is associated with reduced survival (Guazzi et al. 2013a Gerges et al. 2015; Gorter et al. 2018a) . Most recently, Gorter et al. showed that CpcPH-HFpEF patients display greater reduction in PA compliance associated with higher PVR and E a during exercise due to impaired RV contractile reserve, suggesting that measurement of these exercise haemodynamic parameters is important for identifying CpcPH-HFpEF patients (Gorter et al. 2018a ). This study also provides new evidence that RV function and functional preserve may be potential therapeutic targets for management of CpcPH-HFpEF in the future (Gorter et al. 2018a) . The use of PAC, E es /E a and TAPSE/PASP, either at rest or during exercise, is undergoing validation for clinical utility at this time.
How common is CpcPH-HFpEF?
Data from several recent catheter-based studies are available, although varying definitions are being used. In a large retrospective University of Pittsburgh Medical Center (UPMC) cohort, the prevalence of a high DPG, PVR and TPG was evaluated in patients with HFpEF who had a mean PAP ࣙ25 mmHg. In this study the prevalence of DPG ࣙ7 mmHg, PVR ࣙ3 Wood units and TPG >12 mmHg in 2587 patients with PH-HFpEF was 13.7%, 34.2% and 48.9%, respectively (Vanderpool et al. 2018) . In Austria, retrospective and prospective studies found CpcPH (DPG ࣙ7 mmHg) in 22.6% and 18.8% of 217 and 138 patients with PH-HFpEF, respectively (Gerges et al. 2015) . A recent study with the combined Northwestern/San Paolo cohort, CpcPH (DPG ࣙ7 mmHg) was met by 10% of 219 patients with HFpEF . For a smaller sample size, a recent multicentre retrospective study across Italy and Israel found CpcPH (DPG ࣙ7 mmHg) in 38% of 86 patients with PH-HFpEF (Adir et al. 2017) . In addition, a prospective cohort at Tufts Medical Center found that 36% of 73 patients with PH-HFpEF met the CpcPH definition of a DPG ࣙ7 mmHg (Al-Naamani et al. 2015) .
Regardless of whether LVEF is preserved or reduced, the prevalence of CpcPH in patients with left heart disease in the UPMC cohort was 11.7%, 36.2% and 45.9%, based on DPG (ࣙ7 mmHg), PVR (ࣙ3 Wood units) and TPG (>12 mmHg), respectively (Vanderpool et al. 2018) . CpcPH (DPG ࣙ7 mmHg) was also noted in 13% of patients with left heart disease in a Johns Hopkins cohort and 13% of patients with PH in a Vanderbilt cohort (Tampakakis et al. 2015; Assad et al. 2016; Vanderpool et al. 2018) . In cohorts from Austria and the Netherlands, CpcPH (DPG ࣙ7 mmHg) was noted J Physiol 597.4 in 12% of patients with heart failure and in 24.7% of patients with PH, respectively (Gerges et al. 2015; Gorter et al. 2018b) . In Japan, 3% of heart failure patients met the CpcPH definition of a DPG ࣙ7 mmHg (Ibe et al. 2016) . Accordingly, if heart failure affects approximately 6.5 million patients in the USA, then roughly 0.4 million (ranging between 0.2 and 0.6 million) of those patients are estimated to suffer from CpcPH-HFpEF.
What causes pulmonary vascular complications in HFpEF?
The left ventricle is designed to be filled with and to eject blood against the high-resistance systemic circulation, producing adequate cardiac output of 4-6 L of blood per minute to provide oxygen to the entire body. Each single beat of the heart consists of two major components, diastole, the period of LV relaxation and filling, and systole, the period of LV ejection. In a healthy heart, 75-90% of LV filling occurs during early diastole, and the remainder of LV filling occurs during late diastole when there is atrial contraction. The healthy left ventricle can effectively pull in blood to an adequate preload volume (EDV) at a normal filling pressure, but in patients with HFpEF, due to abnormal active relaxation and increased passive stiffness of the left ventricle, normal cardiac filling and output can only be achieved by a compensatory elevation in filling pressure within the left ventricle and a high LA pressure to push blood into the chamber. In this setting, increased LA pressure can then back up into the pulmonary circulation, leading to increased pulmonary venous pressure, which is in turn transferred to pulmonary capillaries, causing damage to the alveolar-capillary barrier (also known as alveolar-capillary stress failure) (West & Mathieu-Costello, 1995) . The alveolar-capillary barrier of the human lung is extremely thin to allow rapid gas exchange by passive diffusion. It consists of three layers, the capillary endothelium, the extracellular matrix (interstitial space) and the alveolar epithelium, with sufficient strength to maintain its integrity and to limit fluid leak into the interstitial space and alveolus. Normally, the endothelial permeability within the alveolar-capillary barrier is very low (approximately 4 times less than pulmonary veins or arteries) with low intracellular Ca 2+ levels to keep the interendothelial junctions closed, and fluid is continuously cleared from the alveolar surface by Na + transport through the epithelial sodium channel (ENaC) and the Na + /K + -ATPase (see reviews in depth by Sukriti et al. 2014; Huppert & Matthay, 2017) . Pressure-induced elevation of intracellular calcium-mediated endothelial retraction, activation of the calcium-permeable transient receptor potential vanilloid 4 (TRPV4) channels, and impaired resorption of alveolar fluid by ENaC are apparently involved in disruption of the integrity of the alveolar-capillary unit, characterized by increased capillary permeability, fluid filtration into interstitial space and reduced fluid removal from the alveolar surface. This leads to pulmonary oedema, which impairs gas exchange and leads to hypoxaemia and dyspnoea. When elevation in filling pressures is sustained, the alveolar-capillary membrane can undergo a compensatory remodelling process characterized by increased extracellular matrix thickening and proliferation, which, along with increased fluid storage/clearance, protect against pulmonary oedema in patients with chronic heart failure (Dixon et al. 2013) . However, over time, excessive extracellular matrix remodelling, inflammation, endothelial dysfunction, myofibroblasts proliferation and alveolar fluid reabsorption contribute to a persistent decrease in capillary-alveolar membrane conductance and gas exchange, ultimately leading to further dyspnoea with even mild exertion (see reviews in depth by Dayeh et al. 2016; Guazzi & Naeije, 2017) . In fact, a low diffusion capacity for carbon monoxide (DLCO) of <45% has been found even at rest in nearly half of the patients with PH-HFpEF (Hoeper et al. 2016) . As disease progresses further, structural and functional changes regulated by chronic elevation in capillary pressure also trigger vasoconstriction and promote remodelling in the pulmonary arteries and veins, with various combinations of intimal proliferation, medial hypertrophy and adventitial thickening (Delgado et al. 2005; Rich & Rabinovitch, 2008; Chen et al. 2012; Hunt et al. 2013; Lai et al. 2016; Guazzi & Naeije, 2017; Fayyaz et al. 2018) . Particularly noteworthy, using urokinase plasminogen activator receptor (uPAR) as an anatomical venous marker, a recent study found that intima, media and adventitia in veins and arteries were significantly remodelled to similar degrees in patients with PH-LHD and in rats with aortic banding (Hunt et al. 2013) . Additionally, medial hypertrophy of muscular pulmonary arteries appears to be the most common pathological finding in patients with at-risk PH-LHD. The greater medial hypertrophy is correlated with higher pulmonary pressure (Delgado et al. 2005) . It is also noted that pulmonary arterial intimal remodelling is the least common pathological feature and has the weakest correlation with PH severity (Lai et al. 2016; Fayyaz et al. 2018) . In a recent study, venous and small vessel intimal thickening were found to be more severe than arterial intimal thickening in patients with PH-HFpEF (Fayyaz et al. 2018) . Collectively, the above attributes describe the patients with CpcPH-HFpEF -patients whose PH involves remodelling of alveolar-capillary and pre-capillary small pulmonary arteries in addition to the passive increase in pulmonary artery pressure. This is in contrast to the patients with IpcPH-HFpEF, whose PH simply rises passively in response to the increase in filling pressure without significant small pulmonary artery remodelling (Fig. 2) .
Animal models of PH-HFpEF
At present, the management of PH-HFpEF is mostly based on the treatment and relief of the underlying HFpEF. While current guidelines recommend management of optimal volume and cardiac filling pressure with diuretics and systemic blood pressure control, no specific therapies are available for reducing mortality and hospitalization in patients with PH-HFpEF. Thus, there is an important unmet need for developing and using animal models to explore potential mechanisms and new treatment options for this disease. Current animal models of PH-HFpEF are adopted from HFpEF models or are developed based on pathophysiological features, comorbidities and other confounding factors, including cardiac pressure overload models, obesity and diabetes models, metabolic syndrome models and models that combine all attributes. Aortic banding, either transverse aortic constriction or supracoronary aortic banding, is the most common and successful surgical model for pressure overload-induced cardiac hypertrophy and HFpEF (Rockman et al. 1991; Litwin et al. 1995) . Aortic-banded mice and rats were found to develop PH, which was evident from increased lung weight, pulmonary fibrosis and remodelling, elevated pulmonary artery pressure and RV hypertrophy (Dai et al. 2004; Chen et al. 2012; Hunt et al. 2013; Lu et al. 2016) . In addition, elevated NT-proBNP plasma levels, alveolar-capillary wall thickening and perivascular fluid cuff formation along extra-alveolar vessels were observed in a recently established aortic-banded cat model of PH-HFpEF (Wallner et al. 2017) . However, aortic banding models cause acute and severe pressure overload compared to the chronic process observed in the human disease. The Dahl salt-sensitive rat, which is hypersensitivity to sodium intake, is another commonly used model for HFpEF-based studies. When fed with a high-salt diet (8% NaCl in most studies) from the age of 7-9 weeks, Dahl salt-sensitive rats exhibit progressive LV concentric hypertrophy, diastolic dysfunction, preserved LVEF and renal failure at the age of 12 weeks (Doi et al. 2000; Klotz et al. 2006; Lee et al. 2017) . Pulmonary oedema and pulmonary vein fibrosis have also been observed in this model, but no catheter-based haemodynamics have been reported (Doi et al. 2000; Nishi et al. 2006; Iwasaki et al. 2016 ).
• While some patients with HFpEF develop CpcPHHFpE or IpcPH-HFpEF, it is noted that some patients never develop PH-HFpEF, suggesting that pathological changes of pulmonary capillaries and small arteries in response to increased filling pressure are not the only factors involved in the development of PH-HFpEF (Thenappan et al. 2011) . Recent studies have found that features of metabolic syndrome, including obesity, diabetes, hyperglycaemia, insulin resistance, hypertension and coronary artery disease (CAD), may affect the development of PH in the setting of HFpEF (Oktay et al. 2013; Farr et al. 2016) . In fact, the prevalence of metabolic syndrome is observed in more than 94% of patients with PH-HFpEF (Robbins et al. 2009 ). The mouse with leptin deficiency (ob/ob) is the most used obesity and diabetic animal model. In addition to evident diastolic dysfunction with impaired LV relaxation, ob/ob mice have been shown to exhibit macrophage infiltration, myofibroblast proliferation, pulmonary arterial remodelling and RV hypertrophy at the age of 12 weeks (Christoffersen et al. 2003; Van den Bergh et al. 2008; Aytekin et al. 2014) . The high fat diet (HFD)-fed mouse is another commonly used model for obesity, impaired glucose tolerance, insulin resistance, type 2 diabetes and LV diastolic dysfunction. Komuro & Rosenzweig (1967) reported that combined HFD (2 g/kg of lanolin, composed of cholesterol and oxycholesterol) and pneumonectomy induced pulmonary hypertension and pulmonary atherosclerosis in rabbits. HFD treatment (60% lipids/kcal, ranging from 8-20 weeks) has also been shown to induce LV hypertrophy, increased LVEDP with preserved LVEF, pulmonary arterial remodelling, elevated pulmonary artery pressure and RV hypertrophy in the most widely used C57BL/6J mice and in apolipoprotein (apoE)-deficient mice (Hansmann et al. 2007; Kelley et al. 2014 Kelley et al. , 2017 Meng et al. 2017) . Recently, Kelly et al. exposed 36 inbred and wild-derived mouse strains to 20 weeks of HFD and identified AKR/J as the strain most susceptible to HFD-induced PH-HFpEF . Of note, the observed increase in severity of PH in HFD-exposed AKR/J mice (RV systolic pressure ß37 mmHg) was close to that observed in patients with PH-HFpEF (RV systolic pressure range 46-51 mmHg). Interestingly, despite HFD-treated C57BL/6J and AKR/J mice developing a comparable degree of obesity, glucose intolerance and hyperglycaemia, changes in RVSP were moderate in C57BL/6J mice Meng et al. 2017) . Kelly et al. also found that the NOD/ShiLtJ mouse, which develops autoimmune type 1 diabetes, was the most resistant strain to HFD-induced PH-HFpEF. In contrast, the NON/shiLtJ mouse, which is sensitive to HFD-induced type 2 diabetes, was highly susceptible to the development of PH-HFpEF, suggesting that type 2 diabetes may be an important pathophysiological abnormality potentially leading to the development of PH-HFpEF Meng et al. 2017) .
Another recently discovered HFpEF model is the obese ZSF1 rat, which is generated by crossing lean female Zuker diabetic fatty rats (ZDF, +/fa) with lean male spontaneous hypertensive heart failure rats (SHHF, +/fa cp ) (Tofovic et al. 2000) . At the age of 8 weeks, obese ZSF1 rats are diabetic with hyperglycaemia, dyslipidaemia and hypertension (Bilan et al. 2011) . As disease progresses, obese ZSF1 rats show elevated LVEDP, preserved LVEF, LV hypertrophy, LA dilatation, increased cardiomyocyte stiffness, pulmonary congestion, effort impairment and signs of renal failure at age 20 weeks (Hamdani et al. 2013; Leite et al. 2015; Franssen et al. 2016; van Dijk et al. 2016) . With the combined treatment of SU5416 (commonly known as Sugen), a vascular endothelial growth factor (VEGF) receptor blocker known to induce lung endothelial injury and apoptosis (Taraseviciene-Stewart et al. 2001) , in 8-week-old obese ZSF1 rats for 14 weeks, the SU5416-exposed obese ZSF1 rats displayed PH-HFpEF characterized by elevated RV systolic pressure (ß38 mmHg) accompanied with increased PVR, pulmonary arterial remodelling and RV hypertrophy (Lai et al. 2016) . Interestingly, a correlation between impaired glucose uptake by skeletal muscle and elevated pulmonary pressures was observed using this model (Lai et al. 2016) , suggesting a broader set of mechanisms contributed by multiple organs may be involved in the regulation of PH-HFpEF. Additionally, several large animal models, such as aged dogs with renal wrapping-induced diastolic dysfunction, Ossabaw swine with metabolic syndrome and high fat/cholesterol diet-exposed diabetic pocrine, have demonstrated the role of ageing and metabolic syndrome in the development of HFpEF; however, their cardiopulmonary function and structure require future studies (Munagala et al. 2005; Trask et al. 2012; van den Heuvel et al. 2012 ).
Summary and future directions
While we still have no approved specific therapy or even a consensus treatment strategy at present for patients with PH in the setting of HFpEF, recent studies have advanced our knowledge and understanding in terms of more precise haemodynamic definitions, classification of subtypes, underlying pathophysiology, standardization of diagnosis and prognosis methodologies, as well as the development of new and relevant animal models. Although the search for effective therapies for PH-HFpEF remains challenging due to phenotypic heterogeneity of the disease, substantial efforts made by researchers over the years have helped to shape a consensus that targeted therapies to specific subtypes of PH-HFpEF may be essential for providing a significant positive impact on patient outcomes.
We would propose five major areas that could advance the field:
(1) Precision medicine targeting of the more severe New mechanism-based therapeutics should attempt to target the diverse phenotype of disease by improving metabolism and pulmonary vascular remodelling. Suggested models include AMPK and sirtuin activators based on metformin, perhaps in combination with pulmonary vasodilatory agents, similar to experiences with nitrite and metformin (Lai et al. 2016) . Combination therapy targeting the pulmonary vasculature, metabolic syndrome and left ventricular relaxation may be required. (4) Limiting the confounding effect of deconditioning.
In our experience, our HFpEF patients are extremely sedentary and deconditioned. Simple participation in our trials increases their activity and confidence in ability to exercise, with observed effects that are much greater than the 'learning effect' observed with repeat six-minute walk testing. This creates background noise for any outcome measure based on exercise. We would propose lead-in cardiopulmonary rehabilitation prior to enrolment, similar to strategies that were shown effective with lung volume reduction surgery (Fishman et al. 2001 (Fishman et al. , 2003 . (5) Continuing to advance development of robust and predictive pre-clinical models of HFpEF and PH-HFpEF. Ultimately, the field may be advanced by the discovery of molecular therapies that directly improve the diastolic function of the left ventricle at rest and during exercise or fluid challenge stress. It will be necessary to test these agents in appropriate models and then advance to the clinic in well-defined patient populations.
In conclusion, establishing a definitive consensus for haemodynamic phenotyping is still a critical first step in providing important new insights into this emerging disease and in driving the research field of PH-HFpEF forward. As individuals with phenotypic variations are noted to have different response to drug treatments, future trials with well-defined and carefully selected patient populations may help to identify the corresponding prevention and treatment strategies. Finally, referral to PH care centres is recommended for treatment of patients in an effort to optimize clinical decision making and potential outcome.
